Market Overview

Why Kintara's Stock Is Trading Higher Today

Share:
Why Kintara's Stock Is Trading Higher Today

Kintara Therapeutics (NASDAQ: KTRA) shares are trading higher on Monday after Aegis Capital initiated coverage on the stock with a Buy rating and announced a price target of $6 per share.

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors.

The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.

Kintara Therapeutics shares were trading up 7.50% at $1.72 during the time of publication Monday. The stock has a 52-week high of $1.95 and a 52-week low of 38 cents.

Latest Ratings for KTRA

DateFirmActionFromTo
Sep 2020Aegis CapitalInitiates Coverage OnBuy

View More Analyst Ratings for KTRA
View the Latest Analyst Ratings

 

Related Articles (KTRA)

View Comments and Join the Discussion!

Posted-In: why it's movingPenny Stocks Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
WMTOppenheimerMaintains152.0
FBOppenheimerMaintains300.0
ASHEvercore ISI GroupInitiates Coverage On80.0
RPMEvercore ISI GroupInitiates Coverage On90.0
DOWEvercore ISI GroupInitiates Coverage On58.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com